Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLS | O94925 | 2/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | BACE1 | P56817 | 2/20 | 0.47 |
| ▸ | CTSD | P07339 | 1/20 | 0.47 |
| ▸ | FPR3 | P25089 | 1/20 | 0.45 |
| ▸ | FPR2 | P25090 | 1/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | ACKR3 | P25106 | 1/20 | 0.44 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.43 |
| ▸ | KDM1A | O60341 | 1/20 | 0.42 |
| ▸ | FEN1 | P39748 | 1/20 | 0.42 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.42 |
| ▸ | GPR119 | Q8TDV5 | 3/20 | 0.41 |
| ▸ | FAAH | O00519 | 1/20 | 0.41 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7686804 | 1.00 | GLS (0.51) | GLSMEN1ALDH1A1MAPTKMT2A | |
| SCHEMBL7686514 | 1.00 | GLS (0.51) | GLSMEN1ALDH1A1MAPTKMT2A | |
| SCHEMBL7692869 | 0.95 | GLS (0.49) | GLSMEN1ALDH1A1MAPTKMT2A | |
| SCHEMBL11980483 | 0.92 | GPR119 (0.48) | GLSMEN1ALDH1A1MAPTKMT2A | |
| SCHEMBL7685622 | 0.92 | MEN1 (0.52) | GLSMEN1ALDH1A1MAPTKMT2A | |
| SCHEMBL7691100 | 0.92 | MEN1 (0.52) | GLSMEN1ALDH1A1MAPTKMT2A | |
| SCHEMBL758457 | 0.92 | MEN1 (0.52) | GLSMEN1ALDH1A1MAPTKMT2A | |
| SCHEMBL20310041 | 0.88 | MEN1 (0.51) | GLSMEN1ALDH1A1MAPTKMT2A | |
| SCHEMBL1070437 | 0.88 | MEN1 (0.51) | GLSMEN1ALDH1A1MAPTKMT2A | |
| SCHEMBL8555556 | 0.88 | MEN1 (0.51) | GLSMEN1ALDH1A1MAPTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6579871-B2 | Phenyl oxazoles or thiazoles | ELI LILLY AND COMPANY | 2003-06-17 | — | — | US | disclosed |
| EP-0971709-B1 | NOVEL COMPOUNDS USEFUL AS NEURO-PROTECTIVE AGENTS | LILLY CO ELI (US) | 2003-05-21 | — | — | EP | disclosed |
| US-20030050311-A1 | Methods of using novel compounds as neuro-protective agents | PANETTA JILL ANN (US) | 2003-03-13 | — | — | US | disclosed |
| US-20020177595-A1 | Novel compounds useful as neuro-protective agents | PANETTA JILL ANN (US) | 2002-11-28 | — | — | US | disclosed |
| US-6472387-B1 | Methods of using compounds as neuro-protective agents | ELI LILLY AND COMPANY | 2002-10-29 | — | — | US | disclosed |
| US-6448396-B2 | 2-((3,5-DIALKYL-4-HYDROXYPHENYL-4-(2-(AMINOALKYLPHENOXY)ETHYL) OXAZOLES; ANTIISCHEMIC AGENTS; REPERFUSION INJURY OF PERIPHERAL ORGANS; FREE RADICAL ANTAGONISTS; PARKINSON'S AND ALZHEIMER'S DISESES; DOWN'S SYNDROME; AMYOTROPHIC LATERAL S. | ELI LILLY AND COMPANY | 2002-09-10 | — | — | US | disclosed |
| US-6423709-B1 | FOR THERAPY OF ALZHEIMER'S DISEASE, PARKINSON'S DISEASE, AMYTROPHIC LATERAL SCLEROSIS OR CEREBRAL TRAUMA IN A MAMMAL | ELI LILLY AND COMPANY | 2002-07-23 | — | — | US | disclosed |
| US-20020065274-A1 | METHODS OF USING NOVEL COMPOUNDS AS NEURO-PROTECTIVE AGENTS | PANETTA JILL ANN (US) | 2002-05-30 | — | — | US | disclosed |
| US-6380213-B1 | PHENYL OXAZOLES, THIAZOLES, OXAZOLINES, OXADIAZOLES AND BENZOXAZOLES | ELI LILLY AND COMPANY | 2002-04-30 | — | — | US | disclosed |
| US-20020007071-A1 | Benzimidzolyl neuropeptide Y receptor antagonists | BRITTON THOMAS CHARLES (US) | 2002-01-17 | — | — | US | disclosed |
| WO-1999009829-A1 | METHOD FOR TREATING PAIN | ELI LILLY AND COMPANY (US) | 1999-03-04 | — | — | WO | disclosed |
| WO-1999009979-A1 | METHOD FOR TREATING NEUROPATHIC PAIN | ELI LILLY AND COMPANY (US) | 1999-03-04 | — | — | WO | disclosed |
| WO-1999009980-A1 | METHOD FOR TREATING PAIN | ELI LILLY AND COMPANY (US) | 1999-03-04 | — | — | WO | disclosed |
| EP-0871442-A1 | BENZIMIDZOLYL NEUROPEPTIDE Y RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY (US) | 1998-10-21 | — | — | EP | disclosed |
| US-5776931-A | TREATING PHYSIOLOGICAL DISORDER ASSOCIATED WITH EXCESS OF NEUROPEPTIDE Y | ELI LILLY AND COMPANY (US) | 1998-07-07 | — | — | US | disclosed |
| WO-1998015274-A1 | NOVEL COMPOUNDS USEFUL AS NEURO-PROTECTIVE AGENTS | ELI LILLY AND COMPANY (US) | 1998-04-16 | — | — | WO | disclosed |
| EP-0789688-A4 | INDOLYL NEUROPEPTIDE Y RECEPTOR ANTAGONISTS | LILLY CO ELI (US) | 1997-11-19 | — | — | EP | disclosed |
| EP-0789688-A1 | INDOLYL NEUROPEPTIDE Y RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY (US) | 1997-08-20 | — | — | EP | disclosed |
| WO-1997025041-A1 | BENZIMIDZOLYL NEUROPEPTIDE Y RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY (US) | 1997-07-17 | — | — | WO | disclosed |
| WO-1997009308-A1 | INDOLYL NEUROPEPTIDE Y RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY (US) | 1997-03-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020007071-A1 | Benzimidzolyl neuropeptide Y receptor antagonists | NPY1R, NPY2R, NPY5R | GLS 728/4885MEN1 815/4885ALDH1A1 4251/4885 |
| US-20020177595-A1 | Novel compounds useful as neuro-protective agents | NLN, PRDX5, TXN2 | GLS 125/4885MEN1 4155/4885ALDH1A1 1209/4885 |
| US-20020065274-A1 | METHODS OF USING NOVEL COMPOUNDS AS NEURO-PROTECTIVE AGENTS | NLN, GAP43, TXN2 | GLS 94/4885MEN1 3950/4885ALDH1A1 1309/4885 |
| US-20030050311-A1 | Methods of using novel compounds as neuro-protective agents | NLN, GAP43, TXN2 | GLS 94/4885MEN1 3950/4885ALDH1A1 1309/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.